Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 6.38%.

  • GeneDx Holdings' EBITDA Margin rose 38400.0% to 6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year increase of 314400.0%. This contributed to the annual value of 16.99% for FY2024, which is 695800.0% up from last year.
  • Latest data reveals that GeneDx Holdings reported EBITDA Margin of 6.38% as of Q3 2025, which was up 38400.0% from 10.44% recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBITDA Margin high stood at 75.8% for Q3 2021, and its period low was 503.28% during Q4 2022.
  • Its 5-year average for EBITDA Margin is 95.22%, with a median of 69.52% in 2021.
  • In the last 5 years, GeneDx Holdings' EBITDA Margin crashed by -4337500bps in 2022 and then skyrocketed by 4591300bps in 2023.
  • GeneDx Holdings' EBITDA Margin (Quarter) stood at 69.52% in 2021, then tumbled by -624bps to 503.28% in 2022, then soared by 91bps to 44.15% in 2023, then soared by 113bps to 5.59% in 2024, then plummeted by -214bps to 6.38% in 2025.
  • Its EBITDA Margin stands at 6.38% for Q3 2025, versus 10.44% for Q2 2025 and 7.41% for Q1 2025.